OTCMKTS:VACBF

Nykode Therapeutics AS (VACBF) Stock Price, News & Analysis

$0.30 0.00 (0.00%)
As of 11/13/2026

About Nykode Therapeutics AS Stock (OTCMKTS:VACBF)

Advanced

Key Stats

Today's Range
$0.30
▼
$0.30
50-Day Range
$0.30
▼
$0.45
52-Week Range
$0.30
▼
$0.45
Volume
N/A
Average Volume
1,000 shs
Market Capitalization
N/A
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Nykode Therapeutics AS is a Norwegian biotechnology company developing immunotherapies and vaccines for cancer and infectious diseases. Formerly known as Vaccibody, the company adopted the Nykode name in 2021.

Its research is based on a modular vaccine platform designed to direct antigens to antigen-presenting cells, with the aim of generating targeted immune responses. The platform supports programs including therapeutic cancer vaccines and vaccines for infectious diseases, with candidates evaluated in clinical development.

Based in Oslo, Nykode conducts research and development in Norway and works with international partners to advance its programs. Its work includes collaborations with pharmaceutical companies and clinical research conducted across multiple regions.

AI Generated. May Contain Errors.

Receive VACBF Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Nykode Therapeutics AS and its competitors with MarketBeat's FREE daily newsletter.

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

VACBF Stock News Headlines

Your Copy is on Hold (Claim it now)
James Altucher, who called NVIDIA in 2008 and SpaceX years before a single share traded, has a new report on Elon Musk's next big industry play. He estimates it could create 1.8 million new millionaires in the coming years, and shows how to position in the company at its center for under $60. Inside: the company's name and ticker, plus an FCC filing James believes reveals Elon's plan to take over a $25 trillion industry. He also flags December 8 as a key date.tc pixel
VACBF Nykode Therapeutics AS - Seeking Alpha
Nykode Therapeutics AS (VACBF) - Yahoo Finance
See More Headlines

VACBF Stock Analysis - Frequently Asked Questions

Nykode Therapeutics AS's stock was trading at $0.1558 at the beginning of the year. Since then, VACBF stock has increased by 90.9% and is now trading at $0.2974.

Shares of VACBF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Industry, Sector and Symbol

Stock Exchange
OTCMKTS
Industry
Biotechnology
Sub-Industry
Biotechnology
Current Symbol
OTCMKTS:VACBF
CIK
N/A
Fax
N/A
Employees
171
Year Founded
N/A

Profitability

EPS (Trailing Twelve Months)
N/A
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
N/A
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
N/A
Return on Assets
N/A

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
N/A
Quick Ratio
N/A

Sales & Book Value

Annual Sales
N/A
Price / Sales
N/A
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
N/A
Price / Book
N/A

Miscellaneous

Outstanding Shares
N/A
Free Float
N/A
Market Cap
N/A
Optionable
Not Optionable
Beta
N/A
 The Best Nuclear Energy Stocks to Buy Cover

Nuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.

Get This Free Report

This page (OTCMKTS:VACBF) was last updated on 11/13/2026 by MarketBeat.com Staff.
From Our Partners